Date: 2016-01-13
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Organovo (USA - CA)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism:
Disease:
Details: * On January 13, 2016, Organovo, a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, announced that its wholly-owned subsidiary, Samsara Sciences, has launched commercial operations. Samsara’s core mission is the provision of high-quality primary human liver cells for a wide variety of in vivo and in vitro research applications. Samsara is expected to serve as a key source of primary human liver cells for Organovo’s needs in the preclinical safety and therapeutic tissues markets, allowing the Company to optimize its supply chain and operating expenses related to cell sourcing and procurement. Organovo sought to establish Samsara as a cell provider in part to support the needs of high-quality cell supply for use in the research and development of bioprinted liver tissue as a potential therapeutic product. Samsara will also provide such cells to life science customers through typical commercial channels. Samsara will offer a comprehensive selection of human hepatic stellate cells – a key cell type in the liver that plays a major role in the development of prevalent diseases such as fatty liver disease and fibrosis. In addition to receiving detailed culture and cryopreservation protocols with each lot of cells, Samsara’s customers will have access to a full portfolio of companion services including the provision of tissue sections, nucleic acids and gene expression data. Human hepatocytes will also be made available through established distribution channels. To achieve its goals, Samsara works closely with key collaborator and liver cell biology expert, Dr. Tatiana Kisseleva and her laboratory at the University of California, San Diego School of Medicine.
Financial terms:
Latest news:
